Enhertu Obtains Regular FDA Approval After Accelerated Approval
May 4, 2022Olumiant Gains FDA Approval to Treat COVID-19 in Adults
May 11, 2022May 5, 2022 – Due to potential for rare but serious blood clots, the FDA has limited emergency use authorization (EAU) for Janssen’s COVID-19 vaccine.
- The vaccine initially received an EUA in February 2021 to prevent COVID-19 in individuals at least 18 years of age. It is now only authorized to prevent COVID-19 in:
- Individuals at least 18 years old for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate.
- Individuals at least 18 years old who elect to receive the Janssen COVID-19 vaccine because they would otherwise not receive a COVID-19 vaccine.
- The FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare but life-threatening condition observed in some recipients of the vaccine, warrants limiting the product’s authorized use.